RemSleep Holdings Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that RemSleep Holdings Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.7K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $117.2K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $203.7K | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $320.7K | Apr 16, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $0 | Jan 5, 2017 |
| FY2014 | Dec 31, 2013 | $0 | Jan 5, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $18.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($756.7K) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $72.3K | Apr 16, 2024 |
| FY2014 | Dec 31, 2014 | $0 | Jan 5, 2017 |
| FY2014 | Dec 31, 2013 | $0 | Jan 5, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.02M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($1.08M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($1.78M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($1.49M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($3.83M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.18M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($3.89M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($412.7K) | Apr 10, 2020 |
| FY2018 | Dec 31, 2017 | ($654.0K) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($199.6K) | Jun 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.77M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($793.5K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($1.77M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($1.22M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($425.7K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($469.8K) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($2.34M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($294.4K) | Apr 10, 2020 |
| FY2018 | Dec 31, 2017 | ($651.5K) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($197.1K) | Jun 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $187.4K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $294.8K | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $337.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $129.3K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $72.6K | Mar 29, 2022 |
| FY2015 | Dec 31, 2015 | $0 | Feb 15, 2017 |
| FY2015 | Dec 31, 2014 | $12.4K | Feb 15, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($502.8K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($683.1K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($791.3K) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($2.23M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($350.0K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($335.3K) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($236.0K) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($111.6K) | Apr 10, 2020 |
| FY2018 | Dec 31, 2017 | ($94.9K) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($133.2K) | Jun 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $124.7K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $147.6K | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $122.3K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $67.3K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $36.7K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $86.9K | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $42.5K | Apr 10, 2020 |
| FY2016 | Dec 31, 2016 | $0 | Apr 18, 2017 |
| FY2016 | Dec 31, 2015 | ($10.3K) | Apr 18, 2017 |
| FY2015 | Dec 31, 2014 | ($4.6K) | Feb 15, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $339.8K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $591.7K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.21M | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $3.36M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $3.50M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $230.7K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $253.3K | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $57.1K | Apr 10, 2020 |
| FY2018 | Dec 31, 2017 | $183.8K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $12.8K | Jun 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $307.7K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $255.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $275.6K | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $652.4K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $880.0K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.10M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $1.26M | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $637.2K | Apr 10, 2020 |
| FY2018 | Dec 31, 2017 | $681.3K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $371.5K | Jun 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.1K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $336.7K | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $930.7K | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $2.71M | Apr 14, 2025 |
| FY2023 | Dec 31, 2021 | $2.62M | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | ($870.5K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | ($1.01M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | ($580.1K) | Apr 14, 2021 |
| FY2019 | Dec 31, 2017 | ($497.5K) | Apr 10, 2020 |
| FY2018 | Dec 31, 2016 | ($358.7K) | Mar 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.29M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($15.27M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($14.19M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($12.41M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($10.39M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($6.57M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($5.39M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($1.50M) | Apr 10, 2020 |
| FY2018 | Dec 31, 2017 | ($1.09M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($435.4K) | Jun 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $214.5K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $463.3K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $719.1K | Apr 14, 2025 |
| FY2021 | Dec 31, 2021 | $3.38M | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | $114.2K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $119.6K | Apr 14, 2021 |
| FY2020 | Dec 31, 2018 | $16.6K | Apr 14, 2021 |
| FY2019 | Dec 31, 2017 | $2.0K | Apr 10, 2020 |
| FY2017 | Dec 31, 2016 | $0 | Jun 28, 2018 |
| FY2017 | Dec 31, 2015 | $108 | Jun 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $182.2K | Jun 28, 2018 |
| FY2017 | Dec 31, 2016 | $85.3K | Jun 28, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.66B | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 1.52B | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 1.46B | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | 1.46B | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 1.23B | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 368.06M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 116.27M | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | 4.32M | Apr 10, 2020 |
| FY2018 | Dec 31, 2017 | 3.61M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 3.27M | Jun 28, 2018 |